JAVELIN Renal 100: Phase 1b dose‐finding study of avelumab + axitinib in
1
st
line mRCC
JAVELIN Renal 100: Phase 1b dose‐finding study of avelumab + axitinib in
•
The objective response rate was 100.0% (95% CI, 54.1‐100.0) based on 6 partial responses
Clinical activity
1
st
line mRCC
•
Responses were ongoing in 5 of 6 patients (83.3%) at the time of analysis
Larkin
et al
. ESMO 2016 Abstract 2513 Poster 775PD
